Expert consensus on risk prevention and control of multiple drug use in elderly patients with cardiovascular diseases and neuropsychiatric diseases

Chinese Society of Clinical Pharmacy of Chinese Medical Association

doi:10.6039/j.issn.1001-0408.2022.23.01

您当前的位置：

首页 >

文章列表页 >

Expert consensus on risk prevention and control of multiple drug use in elderly patients with cardiovascular diseases and neuropsychiatric diseases

更新时间：2023-02-22

- Expert consensus on risk prevention and control of multiple drug use in elderly patients with cardiovascular diseases and neuropsychiatric diseases
- ZHONGGUO YAOFANG Vol. 33, Issue 23, Pages: 2817-2825(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.23.01
  CLC： R926;R972;R971
- Published：15 December 2022，
  
  Received：11 November 2022，
  
  Revised：17 November 2022，
扫描看全文
.Expert consensus on risk prevention and control of multiple drug use in elderly patients with cardiovascular diseases and neuropsychiatric diseases[J].ZHONGGUO YAOFANG,2022,33(23):2817-2825.
DOI：

.Expert consensus on risk prevention and control of multiple drug use in elderly patients with cardiovascular diseases and neuropsychiatric diseases[J].ZHONGGUO YAOFANG,2022,33(23):2817-2825. DOI： 10.6039/j.issn.1001-0408.2022.23.01.

摘要

老年人多重用药非常普遍，其会明显增加药物相互作用和不良反应。心血管疾病合并神经精神疾病是老年人最为常见的多病共患，也是涉及多重用药最多的疾病组合之一。中华医学会临床药学分会组织相关专家，针对心血管疾病合并神经精神疾病的老年患者，利用国外用药风险评估工具，结合相关循证结果，制定了我国《老年人心血管疾病合并神经精神疾病多重用药风险防控专家共识》，进一步推广应用于临床疾病治疗实践，以减少我国老年人的不良临床结局。

Abstract

Multiple drug use is very common in the elderly， which will significantly increase drug interactions and adverse drug reactions. Cardiovascular disease complicated with neuropsychiatric disease is the most common multi-disease comorbidity among the elderly， and it is also one of the disease combinations involving the most multiple drug use. In order to reduce the adverse clinical outcomes of the elderly in China， Chinese Society of Clinical Pharmacy of Chinese Medical Association organized relevant experts to develop

Expert Consensus on Risk Prevention and Control of Multiple Drug Use in Elderly Patients with Cardiovascular Diseases and Neuropsychiatric Diseases

in China by using foreign drug use risk assessment tools and combining relevant evidence-based results， and further promote its application in clinical disease treatment practice to reduce the adverse clinical outcomes of the elderly in China.

关键词

老年人多重用药风险防控心血管疾病神经精神疾病

Keywords

multiple drug userisk prevention and controlcardiovascular diseaseneuropsychiatric disease

references

殷立新，张立辉.特殊人群用药指导丛书：老年人用药指导[M].北京：人民卫生出版社，2012：1-598.

中国老年保健医学研究会老年内分泌与代谢病分会，中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J].中国全科医学，2018，21（29）：3533-3544.

迟俊婷，牛晓丹，阮海慧，等.老年人潜在不适当用药的评估工具及应用进展[J].护理学报，2019，26（23）：36-40.

中华医学会临床药学分会. 2型糖尿病合并慢性肾脏病患者多重用药安全中国专家共识[J].中国全科医学，2022，25（23）：2819-2835.

中国药理学会药源性疾病学专业委员会.中国老年人潜在不适当用药判断标准：2017年版[J].药物不良反应杂志，2018，20（1）：2-8.

American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc，2019，67（4）：674-694.

YANCY C W，JESSUP M，BOZKURT B，et al. 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol，2013，62（16）：e147-e239.

GOLDSTEIN R E，BOCCUZZI S J，CRUESS D，et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction[J]. Circulation，1991，83（1）：52-60.

JAVIDGONBADI D，ANDERSSON B，ABDON N J， et al. Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden：probable dose-related protection from beta-blocker therapy[J]. Open Heart，2019，6（1）：e000963.

EL HADIDI S，ROSANO G，TAMARGO J，et al. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction：ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing[J]. Eur Heart J Cardiovasc Pharmacother，2022，8（2）：187-210.

JUNG S Y，CHOI N K，KIM J Y，et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients[J]. Neurology，2011，77（13）：1229-1234.

PSATY B M，HECKBERT S R，KOEPSELL T D，et al. The risk of myocardial infarction associated with antihypertensive drug therapies[J]. JAMA，1995，274（8）：620-625.

SOLTANI MOHAMMADI S，MAZIAR A，SALIMINIA A. Comparing clonidine and lidocaine on attenuation of hemodynamic responses to laryngoscopy and tracheal intubation in controlled hypertensive patients：a randomized，double-blinded clinical trial[J]. Anesth Pain Med，2016，6（2）：e34271.

BYRD B F，COLLINS H W，PRIMM R K. Risk factors for severe bradycardia during oral clonidine therapy for hypertension[J]. Arch Intern Med，1988，148（3）：729-733.

VOLGMAN A S，CARBERRY P A，STAMBLER B，et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation[J]. J Am Coll Cardiol，1998，31（6）：1414-1419.

杜彪，杜扬，张杰，等.吗氯贝胺与阿米替林对照治疗抑郁症的系统评价[J].中国药业，2015，24（20）：21-23.

刘锐锋，陈满章.西酞普兰与阿米替林治疗抑郁症对照研究的Meta分析[J].中外健康文摘，2012，9（12）：131-133.

常葆凌.心理干预联合氟西汀治疗急性脑卒中后抑郁症的疗效观察[J].中国实用医药，2010，5（34）：194-195.

石洲宝，陈林庆，孙宏，等.安神一号胶囊治疗焦虑症的疗效及安全性：双盲双模拟实验[J].中国临床康复，2004，8（33）：7466-7468.

余为陆，张恒铭，吴广兵，等.长期服用喹硫平、氯氮平对心电图电位、波形的影响[J].医学食疗与健康，2021，19（8）：182-183.

解凯，李德重，刘树林，等.利培酮与氯氮平合并哌罗匹隆应用于难治性精神分裂症的疗效对比分析[J].国际精神病学杂志，2019，46（3）：454-456.

杜彪，赵东国.齐拉西酮与奥氮平治疗精神分裂症的安全性系统评价[J].中国药学杂志，2011，46（13）：1046-1048.

耿娟，季日格.奥氮平治疗精神分裂症有效性和安全性分析[J].临床研究，2016，24（8）：96.

赵泽青，王瑞，于盼盼，等.奥氮平临床不良反应文献分析[J].中国药物警戒，2021，18（3）：260-264.

祁世清，周之平，胡秀秀，等.精神病患者猝死28例临床分析[J].中国民康医学，2009，21（12）：1376.

梁菊芳，何玉球，梁月冰，等.典型与非典型抗精神病药引起精神分裂症患者体位性低血压的对照研究及护理干预[J].中国民康医学，2011，23（21）：2644-2647.

TANNENBAUM C，PAQUETTE A，HILMER S，et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic，antihistamine，GABAergic and opioid drugs[J]. Drugs Aging，2012，29（8）：639-658.

YUAN S，CAMPBELL N，PANDHARIPANDE P，et al. 154 does home benzodiazepine and anticholinergic medica- tion use increase the odds of delirium in older emergency department patients?[J]. Ann Emerg Med，2016，68（4）：S61-S62.

SCHNEIDER L S，DAGERMAN K S，INSEL P. Risk of death with atypical antipsychotic drug treatment for dementia：meta-analysis of randomized placebo-controlled trials[J]. JAMA，2005，294（15）：1934-1943.

PIERSANTI M，CAPANNOLO M，TURCHETTI M，et al.Increase in mortality rate in patients with dementia treated with atypical antipsychotics：a cohort study in outpatients in Central Italy[J]. Riv Psichiatr，2014，49（1）：34-40.

MAUST D T，KIM H M，SEYFRIED L S，et al. Antipsychotics，other psychotropics，and the risk of death in patients with dementia：number needed to harm[J]. JAMA Psychiatry，2015，72（5）：438-445.

SMITH D A，BEIER M T. Association between risperidone treatment and cerebrovascular adverse events：exami- ning the evidence and postulating hypotheses for an underlying mechanism[J]. J Am Med Dir Assoc，2004，5（2）：129-132.

李冲，李东亮，郑华，等.艾司唑仑对老年失眠症患者睡眠质量和日间功能的影响[J].中国组织工程研究与临床康复，2007，11（52）：10483-10485.

宝娜，乔海英.佐匹克隆与艾司唑仑治疗失眠的导眠及日间功能的比较[J/OL].临床医药文献电子杂志，2017，4（90）：17779-17781[2022-11-01]. https：//kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST20- 18&filename=LCWX201790087&uniplatform=NZKPT& v=F5G-cdZQ6fUaINFM44MNsLpNptmfPsRQqL8aoxolCUtML0iNbvT1Gb6XwYALAZis.DOI：10.16281/j.cnki.jocml.2017.90.087https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST20-18&filename=LCWX201790087&uniplatform=NZKPT&v=F5G-cdZQ6fUaINFM44MNsLpNptmfPsRQqL8aoxolCUtML0iNbvT1Gb6XwYALAZis.DOI:10.16281/j.cnki.jocml.2017.90.087.

ELLIS T，CUDKOWICZ M E，SEXTON P M，et al. Cloza- pine and risperidone treatment of psychosis in Parkinson’s disease[J]. J Neuropsychiatry Clin Neurosci，2000，12（3）：364-369.

朱建忠，梁颖茵，朱荣兰，等.利培酮治疗帕金森病合并精神障碍的临床研究[J].吉林医学，2010，31（22）：3670-3672.

康慧敏，郝伟平，王海渊.阿立哌唑与利培酮治疗帕金森病伴发精神症状的临床研究[J].中西医结合心脑血管病杂志，2019，17（24）：4084-4086.

CHEN C L，WANG S Y，CHEN T C，et al. Association between β2-adrenoreceptor medications and risk of Parkinson’s disease：a meta-analysis[J]. Medicina（Kaunas），2021，57（10）：1006.

SAENGPHATRACHAI W，PRADITUKRIT K，OWATTANAPANICH W，et al. The association between developing Parkinson’s disease and β-adrenoceptor acting agents use：a systematic review and meta-analysis[J]. J Neurol Sci，2021，430：120009.

SINGH A，HUSSAIN S，AKKALA S，et al. Beta-adrenergic drugs and risk of Parkinson’s disease：a syste- matic review and meta-analysis[J]. Ageing Res Rev，2022，80：101670.

国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南：第2版[J/OL].中国医学前沿杂志（电子版），2018，10（6）：1-130[2022-11-01]. https：//kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2018&filename=YXQY201806001&uniplatform=NZKPT&v=gXLJChLzUkupU3L15Dcsucf3rGLk- Mm-gtF7R-seQfS0aZ4IJGltyrLG6o5acz6PZhttps://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2018&filename=YXQY201806001&uniplatform=NZKPT&v=gXLJChLzUkupU3L15Dcsucf3rGLk-Mm-gtF7R-seQfS0aZ4IJGltyrLG6o5acz6PZ.

PAZAN F，GERCKE Y，WEISS C，et al. The JAPAN-FORTA （fit for the aged） list：consensus validation of a clinical tool to improve drug therapy in older adults[J]. Arch Gerontol Geriatr，2020，91：104217.

ZIEGELSTEIN R C，MEUCHEL J，KIM T J，et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes[J]. Am J Med，2007，120（6）：525-530.

LABOS C，DASGUPTA K，NEDJAR H，et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction[J]. J De L’association Med Can，2011，183（16）：1835-1843.

SCHELLEMAN H，BRENSINGER C M，BILKER W B，et al. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study[J]. PLoS One，2011，6（6）：e21447.

LÖPPÖNEN P，TETRI S，JUVELA S，et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage：a population-based study[J]. J Neurosurg，2014，120（6）：1358-1363.

QUINN G R，SINGER D E，CHANG Y，et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin[J]. Am J Cardiol，2014，114（4）：583-586.

WALLERSTEDT S M，GLEERUP H，SUNDSTRÖM A，et al. Risk of clinically relevant bleeding in warfarin-treated patients：influence of SSRI treatment[J]. Pharmacoepidemiol Drug Saf，2009，18（5）：412-416.

COCHRAN K A，CAVALLARI L H，SHAPIRO N L，et al.Bleeding incidence with concomitant use of antidepressants and warfarin[J]. Ther Drug Monit，2011，33（4）：433-438.

中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.缺血性卒中基层诊疗指南：2021年[J].中华全科医师杂志，2021，20（9）：927-946.

中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，中国房颤中心联盟心房颤动防治专家工作委员会.心房颤动：目前的认识和治疗建议:2021[J].中华心律失常学杂志，2022，26（1）：15-88.

NAITO R，MIYAUCHI K，YASUDA S，et al. Rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease：a post hoc secon- dary analysis of the AFIRE trial[J]. JAMA Cardiol，2022，7（8）：787-794.

李静，范利，华琦，等.中国老年高血压管理指南2019[J].中国心血管杂志，2019，24（1）：1-23.

国家卫生健康委办公厅.中国脑卒中防治指导规范：2021年版[EB/OL].（2021-08-27）[2022-11-01]. https：//www.cn-healthcare.com/articlewm/20210903/content-1260368.htmlhttps://www.cn-healthcare.com/articlewm/20210903/content-1260368.html.

NISHIO S，WATANABE H，KOSUGE K，et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension[J]. Hypertens Res，2005，28（3）：223-227.

WANG Y C，HSIEH T C，CHOU C L，et al. Risks of adverse events following coprescription of statins and calcium channel blockers：a nationwide population-based study[J]. Medicine （Baltimore），2016，95（2）：e2487.

WIGGINS B S，SASEEN J J，2ndPAGE R L，et al. Re- commendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease：a scientific statement from the American Heart Association[J]. Circulation，2016，134（21）：e468-e495.

WATANABE H，KOSUGE K，NISHIO S，et al. Pharmacokinetic and pharmacodynamic interactions between simva-statin and diltiazem in patients with hypercholesterolemia and hypertension[J]. Life Sci，2004，76（3）：281-292.

AZIE N E，BRATER D C，BECKER P A，et al. The inter- action of diltiazem with lovastatin and pravastatin[J]. Clin Pharmacol Ther，1998，64（4）：369-377.

CHOI D H，CHUNG J H，CHOI J S. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects：role of P-glycoprotein inhibition by lovastatin[J]. Eur J Clin Pharmacol，2010，66（3）：285-290.

BECQUEMONT L，NEUVONEN M，VERSTUYFT C， et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics[J]. Clin Pharmacol Ther，2007，81（5）：679-684.

中国痴呆与认知障碍诊治指南写作组，中国医师协会神经内科医师分会认知障碍疾病专业委员会.2018中国痴呆与认知障碍诊治指南：十：痴呆精神行为症状鉴别诊断和治疗[J].中华医学杂志，2020，100（17）：1290-1293.

POTTIE K，THOMPSON W，DAVIES S，et al. Deprescribing benzodiazepine receptor agonists：evidence-based clinical practice guideline[J]. Can Fam Physician，2018，64（5）：339-351.

BACKMAN J T，OLKKOLA K T，ARANKO K，et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments[J]. Br J Clin Pharmacol，1994，37（3）：221-225.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰